Araba
Campus
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadoras/es de Pfizer (United States) (7)
2021
-
Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with cd-33 positive acute myeloid leukaemia in spain
ClinicoEconomics and Outcomes Research, Vol. 13, pp. 263-277
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 22, Núm. 1
2019
-
Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis
Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715
2017
-
Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 19, Núm. 1
2015
-
Prevalence and clinical features of psoriatic arthritis in psoriasis patients in spain. Limitations of PASE as a screening tool
European Journal of Dermatology, Vol. 25, Núm. 1, pp. 57-63
2007
-
Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME
Archivos de Bronconeumologia, Vol. 43, Núm. 2, pp. 64-72